The Uromigos at ASCO GU 2023: New Data From IMvigor130 With Enrique Grande, MD

By The Uromigos - Last Updated: August 1, 2023

Enrique Grande, MD, PhD, Msc, met with The Uromigos at the 2023 ASCO GU Cancers Symposium to discuss the phase 3 IMvigor130 study that examined 3 treatments for patients with metastatic urothelial carcinoma: chemotherapy, single-agent atezolizumab, or a combination treatment of atezolizumab plus chemotherapy.
Dr. Grande is Director of the Medical Oncology Program and Clinical Research lead at the MD Anderson Cancer Center Madrid.

Post Tags:Uromigos-ASCO GUUromigos-Bladder Cancer